¿ Corvas International Inc., of San Diego, said it entered an agreement with Madison, N.J.-based Schering-Plough Corp., under which development and commercialization rights to recombinant Nematode Anticoagulant Protein 5 (rNAP5) are returned to Corvas. Schering-Plough recently extended their deal to develop oral inhibitors of thrombosis, which is focused on orally administered drugs, and rNAP5 is an injectable drug.

¿ Maxygen Inc., of Santa Clara, Calif., and DSM Anti-Infectives, of Delft, The Netherlands, entered an agreement to utilize Maxygen¿s DNA Shuffling or Molecular Breeding technologies to evolve novel enzymes in the manufacture of antibiotics. Under the terms of the three-year deal, DSM gets global commercialization rights and Maxygen will get payments as well as high-value royalties.